A Retrospective, Observational Analysis of Real-World Maribavir Treatment Patterns for Post-Transplant Refractory Cytomegalovirus Infection (CMVi) in the US (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.24; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "Pts had confirmed post-transplant CMVi (Jan 1, 2015-Mar 31, 2024) and received maribavir for refractory CMVi (defined as val/ganciclovir, cidofovir, foscarnet or letermovir use as 1st line of therapy [LoT] for the 1st CMVi episode). This descriptive research may help clinicians understand the real-world populations receiving maribavir for refractory CMVi, and provides preliminary evidence of higher success rates for maribavir when used earlier in the treatment sequence for refractory CMVi."
Post-transplantation • Real-world • Real-world evidence • Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplant Rejection • Transplantation
|
|
H. Barman 1; A. Smither 1; K. Chacko 1; P. Kumar 1; B. G. Schultz 2; M. Bullano 2; D. K. Gelone 2
|